SCHEDULE 13G: Thomas A. Satterfield, Jr. Discloses 5.2% Passive Stake in Coherus BioSciences, Inc.

Thomas A. Satterfield, Jr. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.2% of Coherus BioSciences, Inc.'s common stock as of April 14, 2025.

Summary

• Thomas A. Satterfield, Jr. reported beneficial ownership of 6,009,514 shares of Coherus BioSciences, Inc. common stock.
• This represents 5.2% of the company's outstanding common stock, based on 115,896,849 shares outstanding as of February 28, 2025, as reported by the issuer in its Annual Report on Form 10-K for the year ended December 31, 2024.
• Mr. Satterfield holds sole voting power and sole dispositive power over 585,000 shares.
• He holds shared voting power and shared dispositive power over 5,424,514 shares.
• The shared ownership includes shares held jointly with his spouse, Rebecca S. Satterfield (100,000 shares), through controlled corporations such as Tomsat Investment & Trading Co., Inc. (750,000 shares), managed funds like Caldwell Mill Opportunity Fund (2,200,000 shares), and partnerships such as A.G. Family L.P. (1,612,514 shares).
• Additionally, Mr. Satterfield has limited powers of attorney for voting and disposition over 687,000 shares held by various family members and trusts, including Thomas A. Satterfield, Sr. (200,000 shares) and Rebecca S. Satterfield (65,000 shares), among others, where these individuals and entities retain the right to receive proceeds from the sale of their respective shares.
• The filing is made under Rule 13d-1(c), indicating a passive investment purpose, explicitly stating that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a passive ownership stake. It contains factual information about share ownership and does not convey positive or negative sentiment regarding the company's performance or outlook, hence a neutral score.

Positives

• The disclosure of a significant passive stake by an individual investor can be viewed as a vote of confidence in Coherus BioSciences, Inc.'s long-term prospects and current valuation.

Future Outlook

The Schedule 13G filing does not contain any forward-looking statements or guidance regarding Coherus BioSciences, Inc.'s future performance or strategic direction, as its purpose is solely to disclose beneficial ownership.

Industry Context

This filing is a routine disclosure of a significant passive ownership stake in Coherus BioSciences, Inc., a biopharmaceutical company. It does not provide specific insights into broader industry trends or competitive dynamics, but rather reflects an individual investor's position within the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive investor's stake, which could be seen as a vote of confidence in the company.

Key Dates

Keywords

Coherus BioSciences, CHRS, Thomas A. Satterfield Jr., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Passive Investment, Biotechnology, Pharmaceuticals